Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectranetics

This article was originally published in The Gray Sheet

Executive Summary

Submits a premarket approval application on June 8 to FDA for peripheral vascular applications of its CVX-300 excimer laser system, Robert DePasqua, company president and CEO announced at the June 15-17 Piper Jaffray Conference in Minneapolis. The firm has been marketing the system for treatment of coronary artery disease since it received agency approval in February ("The Gray Sheet" March 1, p. 9). The firm also expects summer approval of a PMA supplement for its second generation laser system, and a PMA supplement for a third-generation system, the Vitess rapid- exchange laser catheter, will be submitted to FDA in the fall.

You may also be interested in...



FDA Overhauls Its Purple Book

The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.

ICH Syncs Reproductive Toxicity Guidance With Current Science

The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.

Stada Grabs GSK Brands In EU

Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.

UsernamePublicRestriction

Register

MT000795

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel